Afficher la couverture 'Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition | Nakagawa, Shigeki' en grand format
/5

0 avis

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition

Archive ouverte

Nakagawa, Shigeki | Wei, Lan | Song, Won Min | Higashi, Takaaki | Ghoshal, Sarani | Kim, Rosa | Bian, C. Billie | Yamada, Suguru | Sun, Xiaochen | Venkatesh, Anu | Goossens, Nicolas | Bain, Gretchen | Lauwers, Gregory | Koh, Anna | El-Abtah, Mohamed | Ahmad, Noor | Hoshida, Hiroki | Erstad, Derek | Gunasekaran, Ganesh | Lee, Youngmin | Yu, Ming-Lung | Chuang, Wan-Long | Dai, Chia-Yen | Kobayashi, Masahiro | Kumada, Hiromitsu | Beppu, Toru | Baba, Hideo | Mahajan, Milind | Nair, Venugopalan | Lanuti, Michael | Villanueva, Augusto | Sangiovanni, Angelo | Iavarone, Massimo | Colombo, Massimo | Llovet, Josep | Subramanian, Aravind | Tager, Andrew | Friedman, Scott | Baumert, Thomas, F. | Schwarz, Myron | Chung, Raymond | Tanabe, Kenneth | Zhang, Bin | Fuchs, Bryan | Hoshida, Yujin

Edité par CCSD ; Elsevier -

Shigeki Nakagawa, Lan Wei and Won MinSong are co-first author.. International audience. Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal cancer worldwide. HCC prediction and prevention in cirrhosis are key unmet medical needs. Here we have established an HCC risk gene signature applicable to all major HCC etiologies: hepatitis B/C, alcohol, and non-alcoholic steatohepatitis. A transcriptome meta-analysis of >500 human cirrhotics revealed global regulatory gene modules driving HCC risk and the lysophosphatidic acid pathway as a central chemoprevention target. Pharmacological inhibition of the pathway in vivo reduced tumors and reversed the gene signature, which was verified in organotypic ex vivo culture of patient-derived fibrotic liver tissues. These results demonstrate the utility of clinical organ transcriptome to enable a strategy, namely, reverse-engineering precision cancer prevention.

Suggestions

Du même auteur

Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development

Archive ouverte | Qian, Tongqi | CCSD

Background & Aims: There is a major unmet need to assess the prognostic impact of antifibrotics in clinical trials because of the slow rate of liver fibrosis progression. We aimed to develop a surrogate biomarker to predict future...

A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery

Archive ouverte | Crouchet, Emilie | CCSD

International audience. Abstract Chronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options. The lack of clinically relevant/tractable experimental models h...

Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease

Archive ouverte | Fujiwara, Naoto | CCSD

Chargement des enrichissements...